## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($729.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. Allspring Global Investments Holdings LLC Sells 6,253 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20260105T083300 | Somewhat-Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 18.9% in Q3, selling 6,253 shares and retaining 26,800 shares valued at $16.08 million. The company has a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $779.45. Insider selling has also occurred, with Director Christine A. Poon selling 6,500 shares for $4.25 million, though insiders still own approximately 7.02% of the company.

**2. Financiere des Professionnels Fonds d investissement inc. Acquires Shares of 3,171 Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20260104T113629 | Somewhat-Bullish | Relevance: 100%
- Financiere des Professionnels Fonds d'investissement inc. initiated a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during Q3, acquiring 3,171 shares valued at approximately $1.78 million. Despite significant insider selling by a director and a VP, the company reported strong Q3 earnings, beating analyst estimates with EPS of $11.83 and revenue of $3.75 billion. Regeneron maintains a "Moderate Buy" consensus rating from analysts with a target price of $779.45.

**3. Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260103T130818 | Neutral | Relevance: 100%
- This article details the major shareholders of Regeneron Pharmaceuticals (NASDAQ: REGN), highlighting institutional investors like The Vanguard Group and BlackRock. It also examines recent insider trading activities, noting sales and acquisitions by top executives, and provides analysis on what these ownership and trading patterns suggest about the company's valuation and long-term outlook.

**4. Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum**
- Source: Simply Wall Street | 20260105T063715 | Bullish | Relevance: 100%
- Regeneron Pharmaceuticals (REGN) has gained investor attention due to recent share price movements, with the stock closing at $776.31. The company's valuation, despite a narrative fair value near $781, suggests it is currently undervalued, with its broad and advancing pharmaceutical pipeline poised to drive future revenue and earnings growth. The article also highlights potential risks, such as intensifying EYLEA headwinds or regulatory delays, which could impact its upside potential.

**5. Regeneron Shares Maintain Momentum as Key Catalysts Align**
- Source: AD HOC NEWS | 20260104T184108 | Bullish | Relevance: 100%
- Regeneron Pharmaceuticals' shares have significantly outpaced major indices, driven by recent FDA approval for Eylea HD and strong institutional investment. The stock is consolidating near its peak as the market anticipates Q4 2025 earnings, which are expected to provide further insights into Eylea HD's commercial launch and future guidance. Analysts maintain a positive outlook with an average price target indicating further upside.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($108.80M) |
| Sells | 16 ($13.47M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $13M sold (16 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.52 elevated, pricing in significant growth expectations. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Insider buying signal ($108.8M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $80.9B |
| Beta | 0.39 |
| 52W Range | $476.49 - $792.77 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.52 |
| Forward P/E | 19.7 |
| Current P/E | 17.7 |
| YoY Growth | -10.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 0.8% to -1.6% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-2.60), momentum weakening. RSI neutral at 56. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.60% (CS: 18) | Neutral |
| RSI_14 | 56.0 | Neutral |
| MACD Histogram | -2.60 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.262x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $763.23
- **Stop Loss:** $729.23 (4.5% risk)
- **Target:** $797.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $19,080.75
- **Portfolio %:** 19.08%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*